Breathe Well-being vs McKesson

Side-by-side comparison of AI visibility scores, market position, and capabilities

McKesson leads in AI visibility (79 vs 59)
Breathe Well-being logo

Breathe Well-being

ChallengerHealthcare

General

Gurugram India YC W20 digital therapeutics for diabetes/PCOD/thyroid/hypertension reversal serving 150M Indian chronic disease patients; $12.9M total (Accel/General Catalyst Series A 2021 + ₹50Cr pre-Series B 2023) competing with Twin Health.

AI VisibilityBeta
Overall Score
C59
Category Rank
#134 of 596
AI Consensus
77%
Trend
stable
Per Platform
ChatGPT
61
Perplexity
58
Gemini
65

About

Breathe Well-being is a Gurugram, India-based digital therapeutics platform — backed by Y Combinator (W20) with $12.9 million in total funding including a ₹50 crore ($6 million) pre-Series B in 2023 and a $5.5 million Series A in August 2021 led by Accel with General Catalyst, 3one4 Capital, and Scott Shleifer — providing Indians with clinically validated digital programs for reversing and managing Type 2 diabetes, PCOD (polycystic ovarian disease), thyroid disorders, and hypertension through structured weight loss programs combining personalized nutrition coaching, behavioral change support, and continuous glucose monitoring. Founded in 2020 with a mission to help 1 million Indians reverse Type 2 diabetes by 2025, Breathe targets India's 150 million chronic lifestyle disease patients.

Full profile
McKesson logo

McKesson

LeaderHealthcare

General

Largest US pharmaceutical distributor with $308.9B FY2024 revenue; thin-margin distribution triopoly with Cencora and Cardinal Health; US Oncology Network (1,700+ oncologists) is highest-margin segment.

AI VisibilityBeta
Overall Score
B79
Category Rank
#26 of 596
AI Consensus
77%
Trend
stable
Per Platform
ChatGPT
82
Perplexity
76
Gemini
82

About

McKesson Corporation is the largest pharmaceutical distributor in North America and a leading healthcare services company, founded in 1833 in New York City by John McKesson and Charles Olcott and now headquartered in Irving, Texas, trading on NYSE (MCK). The company reported approximately $308.9 billion in revenues for fiscal year 2024 (ending March 31, 2024) under CEO Brian Tyler, making it one of the highest-revenue companies in the United States—though the vast majority of revenues represent pass-through pharmaceutical product costs distributed to approximately 40,000 pharmacies, health systems, and medical providers across North America. McKesson operates through four segments: U.S. Pharmaceutical (the dominant distribution engine), Prescription Technology Solutions (pharmacy benefits technology including CoverMyMeds e-prior authorization), Medical-Surgical Solutions (physician office and extended care medical supply distribution), and International (primarily Canadian distribution through McKesson Canada).

Full profile

AI Visibility Head-to-Head

59
Overall Score
79
#134
Category Rank
#26
77
AI Consensus
77
stable
Trend
stable
61
ChatGPT
82
58
Perplexity
76
65
Gemini
82
55
Claude
85
62
Grok
77

Key Details

Category
General
General
Tier
Challenger
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.